Dexamethasone
Drug8 mg/2 ml dexamethasone IV, 60 minutes before the induction of anaesthesia
NCT Number: NCT04752852
Total thyroidectomy for benign surgical pathologies is associated with risks related to temporary hypocalcaemia and vocal quality dysfunction. Dexamethasone, as an anti-inflammatory steroid, has been proposed to have a physiological effect on hypocalcaemia and voice quality. Investigators conducted a double-blinded controlled trial to assess the effect of preoperative dexamethasone on the vocal dysfunction and hypocalcaemia following thyroidectomy
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Not applicable
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
8 mg/2 ml dexamethasone IV, 60 minutes before the induction of anaesthesia
2 ml normal saline (0.9%) IV, 60 minutes before the induction of anaesthesia
Other names: normal saline (0.9%)
Time frame: 3 days
Hypocalcaemia was defined as a corrected serum calcium level of less than 2 mmol/L.
Time frame: 24 hours
Signs and symptoms of voice dysfunction at 24 hours after thyroidectomy. Voice dysfunction was defined on voice analogue score from 0-100. Participants with Voice Analogue Score of less than 50 were labelled as having voice dysfunction, and participants with score more than 50 were considered as normal.
Holy Family Hospital, Pakistan
Other
Randomised Control Trial on the Use of Prophylactic Steroids in the Prevention of Post-thyroidectomy Hypocalcaemia and Voice Dysfunction
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03869398
Calcium Metabolism Disorders, Endocrine System Diseases
Burlington, Massachusetts, United States
View Trial DetailsNCT07617584
Calcium Metabolism Disorders, Endocrine Gland Neoplasms
Skopje, North Macedonia
View Trial DetailsNCT04785443
Calcium Metabolism Disorders, Endocrine System Diseases
Brest, France
View Trial DetailsNCT06383481
Endocrine System Diseases, Healthy Lifestyle
Erzurum, palandöken, Turkey (Türkiye)
View Trial Details